Shares of London-listed Hikma Pharmaceuticals (LSE: HIK) were down 2% at 1,984.50 pence in mid-morning trading, after the company issued an update on current trading.
Siggi Olafsson, chief executive of the Jordan-based drugmaker, commented: “I am pleased to reiterate our full year guidance for the group in 2019. We continue to execute against our strategic priorities and all three of our businesses continue to deliver good organic growth and profitability in line with our expectations. We are benefitting from our broad and differentiated product portfolios, strong commercial capabilities and tight cost control. We are successfully launching new products while making strategic investments in R&D and partnerships to drive sustainable long-term growth.”
As this is its trading update rather than third-quarter results, the company is not giving a breakdown of sales and earnings at this stage. Numbers for the year ended December 31, 2019 will be published on February 27, 2020.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze